Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome

BACKGROUND Previous studies from our laboratory demonstrated a strong association between an elevated level of chondroitin sulfate (CS) in peritumoral stroma and PSA‐relapse in patients with early stage disease. In this study we determined whether CS levels could predict overall survival in men diag...

Full description

Saved in:
Bibliographic Details
Published in:The Prostate 2009-05, Vol.69 (7), p.761-769
Main Authors: Ricciardelli, Carmela, Sakko, Andrew J., Stahl, Jürgen, Tilley, Wayne D., Marshall, Villis R., Horsfall, David J.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Biological and medical sciences
Chondroitin Sulfates - metabolism
Cohort Studies
Gynecology. Andrology. Obstetrics
Humans
image analysis
Image Processing, Computer-Assisted
Immunohistochemistry
Kaplan-Meier Estimate
Male
Medical sciences
metastasis
Middle Aged
Neoplasm Staging
Nephrology. Urinary tract diseases
Orchiectomy
Predictive Value of Tests
prognosis
Prostate-Specific Antigen - blood
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - pathology
Prostatic Neoplasms - surgery
proteoglycans
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND Previous studies from our laboratory demonstrated a strong association between an elevated level of chondroitin sulfate (CS) in peritumoral stroma and PSA‐relapse in patients with early stage disease. In this study we determined whether CS levels could predict overall survival in men diagnosed with advanced prostate cancer subsequently treated by orchiectomy alone. METHODS CS was localized in archived prostatic tissues by immunohistochemistry, and the level of CS expression as measured by video image analysis was compared in cohorts of 157 and 60 men with early stage or advanced disease, respectively. RESULTS The CS levels in the peritumoral stroma of patients without relapse after treatment for early stage disease was significantly reduced compared to levels in prostate tissue from patients who either relapsed (P = 0.003) or were diagnosed with advanced prostate cancer (P 
ISSN:0270-4137
1097-0045
DOI:10.1002/pros.20926